LEX-WK-KT4WN8CXcrawled 2022-03-03 16:59Z
Switching Study Concludes That Transition From Humira To Samsung Bioepis’s Adalimumab Biosimilar Is Safe and Effective
Emily Rapalino · Big Molecule Watch · Published March 3, 2022
Work details
- author
- Emily Rapalino
- firm or organization
- Goodwin Procter
- publication
- Big Molecule Watch
- practice area
- Health Care and Life Sciences
- published
- 2022-03-03
Citation
Emily Rapalino, Switching Study Concludes That Transition From Humira To Samsung Bioepis’s Adalimumab Biosimilar Is Safe and Effective, Big Molecule Watch (March 3, 2022) [The Library at LexBlog, LEX-WK-KT4WN8CX, lexpid.org/KT4WN8CX]